Transcript Total non-adherent among all enrolled patients

Hepatitis-2015
Orlando, USA
July 20 - 22 2015
Parveen Malhotra
Dr. PARVEEN MALHOTRA
MD,DNB (GASTRO),MNAMS,FIACM,FICP,PGDD
PROFESSOR & HEAD
DEPTT. OF MEDICAL GASTROENTEROLOGY
PGIMS, ROHTAK
THE CULPRIT- NO VACCINATION
REAL CAUSE FOR FIGHT
Sources of Infection for Persons with Hepatitis C
Sexual 15%
Transfusion 10%
(before screening)
Injecting
drug use 60%
Source: Sentinel Counties, CDC
Source: Centers for Disease Control and Prevention
*Nosocomial;
Other* 5%
Health-care work
Unknown 10%
Perinatal
Indian Scenario
 Nearly 12.5 million Indians are suffering from
Hepatitis C affecting the liver.
 Over one lakh people get infected every year
in India, according to the Indian National
Association for the Study of Liver (INASL)
study.
 Every 15th carrier of the HCV is an Indian,
according to a recent report and it is
responsible for as many as one in four cases of
liver cancer and chronic liver disease.
HARYANA SCENARIO
 Initially in Haryana , the prevalence of Chronic
hepatitis C was thought to be comparable to other
parts of India.
 Now the prevalence has drastically increased and is
reaching the levels of areas with high incidence like
Manipur and Punjab.
 There are certain districts like Jind , Kaithal,
Fatehabad, Panipat, Karnal and Sonepat where
Prevalence is touching even 40-50%.
GOOD NEWS FOR HARYANA
 Haryana has become the first state of India where a
separate, dedicated centre has been started under
Department of Medical Gastroenterology, PGIMS,
Rohtak.
 Free treatment of Chronic Hepatitis C has been
started for patients belonging to BPL/SC and at
subsidized rates for general population.
 Twenty thousand patients have been screened over
different parts of haryana.
HEALTH TALKS
HEALTH LECTURES
MEDIA INTERACTIONS
BILONA VILLAGE
AWARENESS TALK AT DERAS
DHABI TEK SINGH VILLAGE
 Patients were treated with standard doses of Pegylated
Interferon and Ribavarin.
 Up till now 1500 patients have completed treatment.
 At present 1500 more patients are currently on
treatment.
GENDER DISTRIBUTION
DEMOGRAPHICAL PROFILE
MARITAL STATUS
AGE DISTRIBUTION
DISTRICT WISE DISTRIBUTION
RISK FACTORS
SYMPTOMATOLOGY
GENOTYPE DISTRIBUTION
SIDE EFFECTS
VIROLOGICAL RESPONSE
Type of report
% patients negative on
HCV RNA report
4th week HCV RNA
60%
12th week HCV RNA
92%
End of therapy (24/48 weeks)
96%
Sustained Virological Response (SVR)
90%
COMPLIANCE RATE
Therapy adherence
n
%
Total enrolled patients
1500
100%
Total adherent among all enrolled patients
1402
93.46%
98
6.54%
Total non-adherent among all enrolled patients
HEPATITIS C HELPLINE
08950012900
CHEER LEADERS
CHEER COUPLE
ACTIVE ROLE OF NGO’S
AWARENESS BY STAFF
MOTIVATION FROM TOP
SOFOSBUVIR- A NEW HOPE
 Up till now 200 patients have been put on treatment
 Majority are on Triple therapy
 Dual therapy – Decompensated cirrhotic or on patient
will
 RVR has been achieved in 95% of patients
 Excellent Compliance rate
CONCLUSIONS
 Haryana has become new hub of Chronic hepatitis C
in India.
 Majority of patients are male and belong to young age
group i.e. 20-40 years of age group.
 Genotype 3 most common and Genotype 4 is more
common in comparison to other parts of Northern
India.
 Most common side effects- A.N. & Depression,
Dyspepsia, Weight loss, Malaise, Generalized
weakness.
 Good compliance and success rates are being achieved.
TAKE HOME MESSAGE
 Most important and first step is appreciation of
problem.
 Next step is to prioritize resources in more prevalent
areas.
 Development of Vaccine and Interferon free regimen is
future dream for hepatitis C.
 Regular Screening camps and awareness in society is
utmost need of hour to curb the menace of this
disease.
 Do not wait till all resources are compiled- Start
moving.
RATIONALE BASED TREATMENT
 Pseudo belief on Alternative Medicines.
 Anti HCV Vs HCV RNA based
ECONOMICAL TREATMENT
STRATEGIES
 SCIENTIFIC AND RATIONALE BASED TREATMENT
 ROLE OF TREATING PHYSICIANS
 ROLE OF STATE AND CENTER
 ROLE OF NGO’S
 ROLE OF PHARMACEUTICAL COMPANIES
Meet the eminent gathering once again at
Hepatitis-2016
Dubai, UAE
October 17 - 19, 2016
Hepatitis– 2016 Website:
hepatitis.omicsgroup.com